Teva Q3 Profit Misses View, Cuts 2017 Outlook; Stock Down


Deutsche Bank AG reissued a buy rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th.

Several analysts have recently weighed in on the stock. The business had revenue of $5.61 billion during the quarter, compared to analysts' expectations of $5.61 billion.

Kåre Schultz, the newly appointed CEO and president of Teva.

ILLEGAL ACTIVITY WARNING: "Barry Investment Advisors LLC Cuts Stake in Teva Pharmaceutical Industries Limited (TEVA)" was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of US & worldwide copyright & trademark legislation. The legal version of this report can be accessed at General Dynamics Corporation had 57 analyst reports since July 31, 2015 according to SRatingsIntel. About 14.11M shares traded. Oppenheimer maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Friday, July 14.

The world's biggest seller of generic drugs, Israel's Teva Pharmaceutical Industries, cut its full-year outlook for the second time this year, blaming price pressure in its USA business and greater competition for its blockbuster multiple sclerosis drug. When considering if perhaps the stock is under or overvalued, the average price target is $21.12 which is 76.3% above where the stock opened today. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since November 2, 2016 and is downtrending. The stock was trading at a distance of -68.23% from its 52-week highs and stands 5.73% away from its 52-week lows.

Watching the trading indicators on shares of Dynacq Healthcare (DYII), we can see that the twenty one day Wilder Moving Average is presently above the 50 day Simple Moving Average. The move on Thursday reduced its market value to about $11 billion. With 25.01 million avg volume, 3 days are for Teva Pharmaceutical Industries L (NYSE:TEVA)'s short sellers to cover TEVA's short positions.

Analysts had been expecting full-year EPS of $4.19 on revenue of $22.6 billion, Thomson Reuters I/B/E/S data showed. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The company's revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.43 EPS. Taking a look at the relative strength indictor, we note that the 14-day RSI is now at 75.50, the 7-day stands at 86.79, and the 3-day is sitting at 91.36. Moreover, Osborne Ptnrs Cap Mngmt Limited Liability Company has 1.05% invested in Johnson & Johnson (NYSE:JNJ) for 55,811 shares. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.



© 2015 Leader Call. All Rights reserved.